HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Metabolife Federal Probe Spurs Release Of Ephedrine Complaint Records

This article was originally published in The Tan Sheet

Executive Summary

An FDA task force will review the 13,000 ephedrine alkaloid patient complaint records Metabolife is releasing in response to publicity surrounding a criminal investigation into whether the company lied about its knowledge of adverse events

You may also be interested in...

Metabolife founder sentenced

Former Metabolife President Michael Ellis is sentenced to six months in prison and ordered to pay a $20,000 fine after pleading guilty to making false statements to federal regulators, according to a judgment filed June 10 in the U.S. District Court for the Southern District of California in San Diego. Ellis told FDA in 1998 that his company had never received any consumer complaints related to its ephedra-containing Metabolife 365. The weight-control supplement firm later released 13,000 patient complaints during a criminal investigation by the Department of Justice (1"The Tan Sheet" Aug. 19, 2002, p. 3)...

Metabolife, Founder Indicted By Jury; Charges “Utterly Baseless,” Firm Says

Metabolife founder Michael Ellis could face up to 40 years in jail and maximum fines of $2 mil. if found guilty of an eight-count indictment laid down in San Diego federal court

Metabolife 356 “Unreasonably Dangerous,” Jury Says In $4.1 Mil. Verdict

Metabolife sold its ephedrine alkaloid-containing Metabolife 356 in a "defective condition unreasonably dangerous to an ultimate user," a Birmingham, Ala. federal jury concluded in four cases Nov. 19

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts